Biocytogen Unleashes Legions of High-Tech Mice to Lure IPO Investors
The major provider of gene-edited lab rodents gets the nod for a Hong Kong listing after abandoning a plan to float shares on Shanghai’s STAR Market Key Takeaways: Gene-edited lab…
RELATED ARTICLES
-
Joinn profits slide as lab monkey build-up backfires
6127.HK 603127.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- Funding boost gets Sunho Biologics over the IPO filing line
-
CStone breaks up with drugs partner as U.S. rollout stalls
2616.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
Discover hidden China stock gems in our weekly newsletter